FRLN Freeline Therapeutics Holdings ADS

Freeline to Present at the Stifel Healthcare Conference

Freeline to Present at the Stifel Healthcare Conference

LONDON, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that Chief Executive Officer Michael Parini will participate in a fireside chat at the Stifel Healthcare Conference being held in New York.

The fireside chat will take place on November 16th at 8:35 am ET. Senior management will also participate in one-on-one investor meetings during the conference.

A live webcast of the fireside chat will be available on the section of Freeline’s website at An archived replay of the fireside chat will be available for approximately 90 days following the fireside chat.

About Freeline Therapeutics

Freeline is a clinical-stage biotechnology company developing transformative adeno-associated virus (AAV) vector-mediated systemic gene therapies. The company is dedicated to improving patient lives through innovative, one-time treatments that may provide functional cures for inherited, systemic debilitating diseases. Freeline uses its proprietary, rationally designed AAV vector and capsid (AAVS3), along with novel promoters and transgenes, to deliver a functional copy of a therapeutic gene into human liver cells, thereby expressing a persistent functional level of the missing or dysfunctional protein into the patient’s bloodstream. The company has clinical programs in hemophilia B, Fabry disease, and Gaucher disease Type 1. Freeline is headquartered in the UK and has operations in Germany and the U.S.

IR Contact:

Naomi Aoki

Senior Vice President, Head of Investor Relations & Communications





EN
09/11/2022

Underlying

FRLNFreeline Therapeutics Holdings ADS

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Freeline Therapeutics Holdings ADS

 PRESS RELEASE
Free
FRLN Freeline Therap...

Freeline to Present New Data on its Gaucher and Parkinson’s Disease Pr...

Freeline to Present New Data on its Gaucher and Parkinson’s Disease Programs at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting Late-breaking oral presentation on results from Phase 1/2 study of FLT201 in Gaucher disease Poster presentation to highlight Freeline’s GBA1 Parkinson’s disease research program LONDON, April 24, 2024 (GLOBE NEWSWIRE) -- today announced the acceptance of multiple abstracts, including one for a late-breaking oral presentation on new clinical data from its Gaucher disease program, at the upcoming American Society of Gene and Cell Thera...

April 24, 2024 1 EN
 PRESS RELEASE
Free
FRLN Freeline Therap...

Acquisition of Freeline by Syncona Becomes Effective

Acquisition of Freeline by Syncona Becomes Effective LONDON, Feb. 20, 2024 (GLOBE NEWSWIRE) -- plc (Nasdaq: FRLN) (“Freeline”) and Syncona Ltd (“Syncona”) today announced that, in connection with Syncona’s acquisition of Freeline by way of a scheme of arrangement (the “Scheme”), the Scheme has been sanctioned by the Court and the court order (together with a copy of the scheme circular published by Freeline on January 18, 2024 (the “Scheme Circular”) has been delivered to the Registrar of Companies.   Accordingly, the Scheme has become Effective in accordance with its terms and the entir...

February 20, 2024 1 EN
 PRESS RELEASE
Free
FRLN Freeline Therap...

Freeline Shareholders Approve Acquisition by Syncona

Freeline Shareholders Approve Acquisition by Syncona LONDON, Feb. 12, 2024 (GLOBE NEWSWIRE) -- plc (Nasdaq: FRLN) (“Freeline”) and Syncona Ltd (“Syncona”) today announced that Freeline’s shareholders have approved the proposal for Bidco 1354 Limited (“Bidco”), a wholly owned subsidiary of Syncona Portfolio Limited (“Syncona Portfolio”), to acquire all shares of Freeline not currently owned by Syncona Portfolio for $6.50 per American Depositary Share (“ADS”) in cash (the “Acquisition”). As previously announced, Freeline and Bidco entered into an implementation agreement on November 22, 20...

February 12, 2024 1 EN
 PRESS RELEASE
Free
FRLN Freeline Therap...

Syncona to Acquire Freeline Therapeutics

Syncona to Acquire Freeline Therapeutics Freeline shareholders to receive $6.50 per American Depositary Share, a 51% premium over closing price prior to announcement of Syncona’s initial proposal on October 18, in an all-cash transaction Based on extensive evaluation of available strategic and financing options, Freeline’s independent directors unanimously recommend transaction as best value for shareholders Syncona to provide $15 million in convertible debt financing to cover Freeline’s near-term capital needs and support ongoing advancement of its programs LONDON, Nov. 22, 2023 (GLO...

November 22, 2023 1 EN
 PRESS RELEASE
Free
FRLN Freeline Therap...

Freeline Presents Positive New Data from Phase 1/2 GALILEO-1 Trial of ...

Freeline Presents Positive New Data from Phase 1/2 GALILEO-1 Trial of FLT201, Its Novel Gene Therapy Candidate, in Gaucher Disease at ESGCT 30th Annual Congress Substantial reduction in lyso-Gb1 substrate levels, an established biomarker of clinical response, observed in first patient treated with FLT201 Increases of several hundredfold over baseline in plasma GCase activity and normalization of cellular GCase levels continue to be observed in first two patients treated with FLT201 FLT201 continues to be well-tolerated, with no serious adverse events Third patient dosed thi...

October 25, 2023 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch